# Alpha Cognition Q3 2026 Revenue Reaches $7.78 Million as ZUNVEYL Prescriptions Climb

> Alpha Cognition reported Q3 2026 revenue of $7.78 million and a loss of $0.28 per share, both ahead of estimates, as ZUNVEYL prescription volume rose 31%.

- Published: 2026-11-11T23:51:35+00:00
- Section: Earnings & Results
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-11/alpha-cognition-q3-2026-earnings
- Source: [Quiver Quantitative](https://www.quiverquant.com/news/ALPHA+COGNITION+%28%24ACOG%29+Releases+Q3+2026+Earnings%2C+Stock+Rises)

## Key takeaways

- Alpha Cognition reported Q3 2026 revenue of $7.78 million, beating estimates of $7.2 million.
- The company posted a loss of $0.28 per share, ahead of the $0.34 loss analysts expected.
- ZUNVEYL prescription volume rose 31% to 10,896 bottles, with 1,639 prescribers and 77% repeat prescriptions.

Alpha Cognition reported Q3 2026 revenue of $7.78 million and a loss of $0.28 per share on November 11, 2026, both ahead of analyst estimates. [Quiver Quantitative](https://www.quiverquant.com/news/ALPHA+COGNITION+%28%24ACOG%29+Releases+Q3+2026+Earnings%2C+Stock+Rises) reported that the company beat the expected loss of $0.34 per share by $0.06 and the revenue estimate of $7.2 million by $598,864. The stock rose 6.47% after market close.

## ZUNVEYL Demand Lifts Alpha Cognition's Quarterly Results

[Alpha Cognition](https://akta.pro/company-profiles/00002hd/alpha-cognition) is a commercial-stage biopharmaceutical company that develops and commercializes ZUNVEYL (benzgalantamine), an FDA-approved oral prodrug therapy for mild-to-moderate Alzheimer's disease, according to akta.pro [company records](https://akta.pro/company-data). The company targets US long-term care facilities through a 60-person field sales force and Medicare Part D coverage of approximately 45 million lives.

[Chartmill](https://www.chartmill.com/news/ACOG/Chartmill-58555-Alpha-Cognition-NASDAQACOG-Posts-Q3-Beat-as-ZUNVEYL-Demand-Builds) reported that ZUNVEYL prescription volume rose 31% to 10,896 bottles, with 1,639 prescribers and 77% repeat prescriptions. Chartmill also reported that the company targets operating profitability in 2027.

Quiver Quantitative reported that two analysts issued price targets for the stock in the last six months, with a median target of $15.0. Naz Rahman of Maxim Group set a target of $12.0 on May 29, 2026, and Raghuram Selvaraju of HC Wainwright & Co. set a target of $18.0 on May 22, 2026.

## Alpha Cognition's Cash Position and ZUNVEYL Launch

The same records show Alpha Cognition held $54.2 million in cash and cash equivalents as of Q1 2026, supporting a path to operating profitability in 2027 on a debt-free balance sheet. The company commercially launched ZUNVEYL in the US long-term care market in March 2025, establishing a 60-person field sales force targeting nursing homes, assisted living facilities and consultant pharmacists. In September 2025, Alpha Cognition priced a $35 million oversubscribed public offering of common shares to build cash reserves for commercialization and pipeline advancement.

## Patent Filing and Board Appointment Precede Results

On October 13, 2026, Stock Titan reported that Alpha Cognition announced the USPTO publication of U.S. Patent Application No. 19/090,242 on October 1, 2026, covering its proprietary manufacturing process for benzgalantamine, the active ingredient in ZUNVEYL. On November 9, 2026, Stock Titan reported that Alpha Cognition appointed Caren Deardorf to its board of directors, effective that day; she brings commercial leadership experience, including leading the launch of SPINRAZA at Biogen, which generated about $2 billion in revenue in its first two years.

## Investor Events Ahead for Alpha Cognition

TradingView reported that CEO Michael McFadden and COO Lauren D'Angelo will participate in a Craig-Hallum Alpha Select Conference on November 17, 2026, and a Stonegate CEO Series fireside chat on December 10, 2026.

## Companies in this story

- [Alpha Cognition company profile](https://akta.pro/company-profiles/00002hd/alpha-cognition) · website: https://www.alphacognition.com

---
News for Agent · https://newsforagent.com/llms.txt